Alligator Bioscience AB (publ) (STO:ATORX)

Market Cap	200.68M
Revenue (ttm)	43.75M
Net Income (ttm)	-131.96M
Shares Out	34.80M
EPS (ttm)	-17.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	279,223
Average Volume	317,625
Open	5.99
Previous Close	5.75
Day's Range	5.60 - 5.99
52-Week Range	3.69 - 1,490.00
Beta	1.35
RSI	53.03
Earnings Date	Jul 10, 2025

About Revance Therapeutics

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 45
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ATORX

Financial Performance

In 2024, Alligator Bioscience AB's revenue was 57.72 million, a decrease of -2.58% compared to the previous year's 59.25 million. Losses were -233.89 million, -5.91% less than in 2023.